Alnylam to Webcast Presentation at TD Cowen 46th Annual Health Care Conference
Alnylam (Nasdaq: ALNY) will present a company overview at the TD Cowen 46th Annual Health Care Conference on Monday, March 2, 2026 at 9:10 am ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
A live audio webcast of the presentation will be available on the Investors section of the Company’s website, www.alnylam.com/events. A replay will be available on the Alnylam website within 48 hours after the event.
About Alnylam Pharmaceuticals
Alnylam (Nasdaq: ALNY) is a leading global biopharmaceutical company and the pioneer of the RNA interference (RNAi) revolution. The Company is focused on developing transformative therapies with the potential to prevent, halt, or reverse disease. For more than two decades, Alnylam has advanced the Nobel-Prize-winning science of RNAi, delivering critical breakthroughs and six approved medicines. Alnylam has medicines available in more than 70 countries and a rapidly expanding and robust pipeline, in addition to consistently being recognized as an exceptional workplace and socially responsible organization. The Company is executing on its Alnylam 2030 strategy to accelerate innovation and scale impact to transform human health. For more information, please visit www.alnylam.com or follow Alnylam on X, LinkedIn, Facebook, Instagram, or YouTube.
View source version on businesswire.com: https://www.businesswire.com/news/home/20260223539046/en/
Alnylam Pharmaceuticals, Inc.
Christine Akinc
(Investors and Media)
617-682-4340
Josh Brodsky
(Investors)
617-551-8276
Source: Alnylam Pharmaceuticals, Inc.